Biologics and Biosimilars Market 2019 | In-depth Analysis by Top Players AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-L

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.
Through the research we tend to believe that the growth of biologics industry maybe slow but high profits during the period of patent may attractive. As to biosimilars, now is a changce for newcomers and they will greatly change the industry.

Free Request Sample of Report: https://www.worldwidemarketreports.com/sample/254965

The Biologics and Biosimilars market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

Furthermore, the Biologics and Biosimilars market revenue is growing because of increasing number of Food and Drug Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017 US FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

North America holds dominant position in the global Biologics and Biosimilars market, owing to presence of major pharmaceutical and biopharmaceutical companies in the U.S. such as AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Novartis, Pfizer, and Sanofi with a great product portfolio in biologics. In 2018, 59 novel drugs and biologics were approved in by FDA’s Center for Drug Evaluation and Research and were launched in the U.S.

Asia Pacific is anticipated to witness significant growth in Biologics and Biosimilars market size because of production and manufacturing of biosimilar products of biologics. A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. For instance, Indian biopharmaceutical company Biocon Ltd., launched two biosimilars CANMAb (trastuzumab) and Krabeva (bevacizumab) in India in year 2014 and 2017 respectively for treatment of several types of cancer.

The worldwide market for Biologics and Biosimilars is expected to grow at a CAGR of roughly 4.5% over the next five years, will reach 272400 million US$ in 2024, from 209400 million US$ in 2019, according to a new WMR study.

Get Free PDF Brochure of Research Report: https://www.worldwidemarketreports.com/quiry/254965

Key players operating in the global Biologics and Biosimilars market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

Market Segment by Type, covers
-Monoclonal Antibodies
-Interferon
-Erythropoietin
-Insulin
-Vaccines
Other

Market Segment by Applications, can be divided into
-Tumor
-Diabetes
-Cardiovascular
-Hemophilia
Other

About Us:
Worldwide Market Reports is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Worldwide Market Reports
Tel: +1 415 871 0703
Email: sales@worldwidemarketreports.com

This release was published on openPR.